jRCT2080224973已完成4 期
An Open-Label, Multi-Center Extension Study to Characterize the Long-Term Safety and Efficacy of BMS-986165 in Subjects with Moderate-to-Severe Plaque Psoriasis
Bristol-Myers Squibb1 个研究点目标入组 60 人开始时间: 待定最近更新:
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- 入组人数
- 60
- 试验地点
- 1
- 主要终点
- -
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 干预模型
- Open Label, Single Arm
- 主要目的
- Treatment Purpose
入排标准
- 年龄范围
- 20age old over 至 No limit（—）
- 性别
- All
入选标准
- •Completion of the protocol-required treatment period in an applicable study of BMS-986165 in moderate-to-severe psoriasis
- •Women must not be pregnant, lactating, or breastfeeding
排除标准
- •Any disease or medical condition that the investigator feels that would make the patient unsuitable for this study.
- •To be eligible for the study, a participant must not have active signs or symptoms of tuberculosis (TB) as judged by the investigator.
结局指标
主要结局
-
Incidence of Adverse Events (AE) and Serious Adverse Events (SAE) [ Time Frame: 96 weeks ]
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
Phase 2 Study of the Efficacy and Safety of BMS-986278 in Pulmonary Fibrosis (IM027-040)Pulmonary FibrosisjRCT2080225297Bristol-Myers Squibb360
招募中
1 期
A Phase 1b/2 Study of BMS-986442 with Nivolumab with or without Chemotherapy in Solid Tumors and Non-small Cell Lung CancerSolid Tumor, Non-small cell lung cancerMedDRA version: 21.1Level: PTClassification code: 10061873Term: Non-small cell lung cancer Class: 100000004864MedDRA version: 21.1Level: LLTClassification code: 10065252Term: Solid tumor Class: 10029104CTIS2022-503108-26-00Bristol-Myers Squibb Services Unlimited Company245
进行中（未招募）
1 期
An Investigational Immuno-Therapy Study of Experimental Medication BMS-986253 Given in Combination with Nivolumab in Patients with Advanced CancersEUCTR2018-000340-26-GBBristol-Myers Squibb International Corporation800
进行中（未招募）
1 期
An Investigational Immuno-Therapy Study of Experimental Medication BMS-986253 Given in Combination with Nivolumab in Patients with Advanced CancersEUCTR2018-000340-26-ITBRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATIO800
进行中（未招募）
1 期
An Investigational Immuno-Therapy Study of Experimental Medication BMS-986253 Given in Combination with Nivolumab in Patients with Advanced CancersAdvanced CancersMedDRA version: 20.0Level: LLTClassification code 10065252Term: Solid tumorSystem Organ Class: 100000004864EUCTR2018-000340-26-ESBristol-Myers Squibb International Corporation378